Evidence map›Paper›PMID 28520087›Full record

Observational studyClinical cardiology2017

Geographic variation and risk factors for systemic and limb ischemic events in patients with symptomatic peripheral artery disease: Insights from the REACH Registry.

Jérémie Abtan, Deepak L Bhatt, Yedid Elbez, Emmanuel Sorbets, Kim Eagle, Christopher M Reid, Iris Baumgartner, David Wu, Mary E Hanson, Hakima Hannachi and 4 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Clinical cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Observational
  11. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jérémie AbtanFACT (French Alliance for Cardiovascular Trials), French Clinical Research Infrastructure Network, University Hospital Departments-FIRE, Hôpital Bichat, Public Assistance Hospitals of Paris, Paris Diderot University, Sorbonne University Paris Cité, and National Institute of Health and Medical Research, U-1148 Paris, France.
Deepak L BhattHeart and Vascular Center, Brigham and Women's Hospital, and Harvard Medical School, Boston, Massachusetts.ORCID http://orcid.org/0000-0002-1278-6245
Yedid ElbezFACT (French Alliance for Cardiovascular Trials), French Clinical Research Infrastructure Network, University Hospital Departments-FIRE, Hôpital Bichat, Public Assistance Hospitals of Paris, Paris Diderot University, Sorbonne University Paris Cité, and National Institute of Health and Medical Research, U-1148 Paris, France.
Emmanuel SorbetsFACT (French Alliance for Cardiovascular Trials), French Clinical Research Infrastructure Network, University Hospital Departments-FIRE, Hôpital Bichat, Public Assistance Hospitals of Paris, Paris Diderot University, Sorbonne University Paris Cité, and National Institute of Health and Medical Research, U-1148 Paris, France.ORCID http://orcid.org/0000-0003-0559-6301
Kim EagleCardiovascular Center, University of Michigan, Ann Arbor, Michigan.
Christopher M ReidMonash University, Clayton, Victoria, Australia and Curtin University, Bentley, Perth, Western Australia.
Iris BaumgartnerUniversity Hospital of Bern, Bern, Switzerland.
David WuMerck & Co., Inc., Kenilworth, New Jersey.
Mary E HansonMerck & Co., Inc., Kenilworth, New Jersey.ORCID http://orcid.org/0000-0003-4785-7207
Hakima HannachiMerck & Co., Inc., Kenilworth, New Jersey.
Puneet K SinghalMerck & Co., Inc., Kenilworth, New Jersey.
Philippe Gabriel StegFACT (French Alliance for Cardiovascular Trials), French Clinical Research Infrastructure Network, University Hospital Departments-FIRE, Hôpital Bichat, Public Assistance Hospitals of Paris, Paris Diderot University, Sorbonne University Paris Cité, and National Institute of Health and Medical Research, U-1148 Paris, France.
Gregory DucrocqFACT (French Alliance for Cardiovascular Trials), French Clinical Research Infrastructure Network, University Hospital Departments-FIRE, Hôpital Bichat, Public Assistance Hospitals of Paris, Paris Diderot University, Sorbonne University Paris Cité, and National Institute of Health and Medical Research, U-1148 Paris, France.
REACH Registry Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with symptomatic peripheral artery disease (PAD) are at high risk of ischemic events. However, data about predictors of this risk are limited. HYPOTHESIS: We analyzed baseline characteristics and 4-year follow-up of patients enrolled in the international REduction of Atherothrombosis for Continued Health (REACH) Registry with symptomatic PAD and no history of stroke/transient ischemic attack to describe annual rates of recurrent ischemic events globally and geographically.

methodsThe primary outcome was systemic ischemic events (composite of cardiovascular death, myocardial infarction, or stroke) at 4 years. The secondary outcome was limb ischemic events (composite of lower limb amputation, peripheral bypass graft, and percutaneous intervention for PAD) at 2 years. Multivariate analysis identified risk factors associated with recurrent ischemic events.

resultsThe primary endpoint rate reached 4.7% during the first year and increased continuously (by 4%-5% each year) to 17.6% by year 4, driven mainly by cardiovascular mortality (11.1% at year 4). Japan experienced lower adjusted ischemic rates (P < 0.01) vs North America. Renal impairment (P < 0.01), congestive heart failure (P < 0.01), history of diabetes (P < 0.01), history of myocardial infarction (P = 0.01), vascular disease (single or poly, P < 0.01), and older age (P < 0.01) were associated with increased risk of systemic ischemic events, whereas statin use was associated with lower risk (P = 0.03). The limb ischemic event rate was 5.7% at 2 years.

conclusionsFour-year systemic ischemic risk in patients with PAD and no history of stroke or transient ischemic attack remains high, and was mainly driven by cardiovascular mortality.

Indexed as

AgedAged, 80 and overAmputation, SurgicalAsiaCause of DeathComorbidityEndovascular ProceduresFemaleFollow-Up StudiesHumansIncidenceIschemiaKaplan-Meier EstimateLatin AmericaMaleMiddle AgedIschemic RiskPeripheral Artery DiseaseVorapaxar

Identifiers

PMID28520087
PMCPMC6490387

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.